{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:51:26Z","timestamp":1790117486820,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4013-6","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:20:50Z","timestamp":1517617250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ"],"prefix":"10.1186","volume":"18","author":[{"given":"Marie","family":"Beguinot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Melanie","family":"Dauplat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lebouedec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Tixier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pomel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-8730","authenticated-orcid":false,"given":"Nina","family":"Radosevic-Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,3]]},"reference":[{"issue":"1","key":"4013_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"4013_CR2","doi-asserted-by":"crossref","unstructured":"Hoffman AW, Ibarra-Drendall C, Espina V, Liotta L, Seewaldt V. Ductal carcinoma in situ: challenges, opportunities, and uncharted waters. Am Soc Clin Oncol Educ Book. 2012:40\u20134.","DOI":"10.14694\/EdBook_AM.2012.32.228"},{"issue":"4","key":"4013_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrclinonc.2015.8","volume":"12","author":"M Morrow","year":"2015","unstructured":"Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol. 2015;12(4):227\u201338.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4013_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/his.12796","volume":"68","author":"JM Pang","year":"2016","unstructured":"Pang JM, Gorringe KL, Fox SB. Ductal carcinoma in situ - update on risk assessment and management. Histopathology. 2016;68(1):96\u2013109.","journal-title":"Histopathology"},{"issue":"39","key":"4013_CR5","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1073\/pnas.1608077113","volume":"113","author":"A Spira","year":"2016","unstructured":"Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, et al. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A. 2016;113(39):10750\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4013_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"4013_CR7","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1158\/1078-0432.CCR-15-1315","volume":"22","author":"L Pusztai","year":"2016","unstructured":"Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New strategies in breast cancer: immunotherapy. Clin Cancer Res. 2016;22(9):2105\u201310.","journal-title":"Clin Cancer Res"},{"key":"4013_CR8","volume-title":"WHO classification of Tumours of the breast","author":"SR Lakhani","year":"2012","unstructured":"Lakhani SR, Ellis IO, Schnitt SJ, Tan PH. In: Van de Vijver MJ, editor. WHO classification of Tumours of the breast. 4th ed. Lyon: IARC Press; 2012.","edition":"4"},{"issue":"2","key":"4013_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"2","key":"4013_CR10","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155\u201368.","journal-title":"Mod Pathol"},{"issue":"2","key":"4013_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241\u201356.","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"4013_CR12","first-page":"1736","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2011. 2011;22(8):1736\u201347.","journal-title":"Ann Oncol 2011"},{"issue":"10","key":"4013_CR13","first-page":"715","volume":"87","author":"F Kwiatkowski","year":"2000","unstructured":"Kwiatkowski F, Girard M, Hacene K, Berlie J. Sem: a suitable statistical software adaptated for research in oncology. Bull Cancer. 2000;87(10):715\u201321.","journal-title":"Bull Cancer"},{"issue":"2","key":"4013_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/(SICI)1096-9896(199702)181:2<200::AID-PATH726>3.0.CO;2-K","volume":"181","author":"AH Lee","year":"1997","unstructured":"Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol. 1997;181(2):200\u20136.","journal-title":"J Pathol"},{"issue":"9","key":"4013_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/jcp.2005.031252","volume":"59","author":"MR Hussein","year":"2006","unstructured":"Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59(9):972\u20137.","journal-title":"J Clin Pathol"},{"issue":"2","key":"4013_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-013-2556-4","volume":"139","author":"A Lal","year":"2013","unstructured":"Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139(2):381\u201390.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4013_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29(3):249\u201358.","journal-title":"Mod Pathol"},{"key":"4013_CR18","doi-asserted-by":"crossref","unstructured":"Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2016;","DOI":"10.1007\/s10549-016-4036-0"},{"issue":"4","key":"4013_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<778::AID-CNCR14>3.0.CO;2-S","volume":"78","author":"MM Black","year":"1996","unstructured":"Black MM, Zachrau RE, Hankey BF, Feuer EJ. Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology? Cancer. 1996;78(4):778\u201388.","journal-title":"Cancer"},{"issue":"2B","key":"4013_CR20","first-page":"1231","volume":"22","author":"H Ben-Hur","year":"2002","unstructured":"Ben-Hur H, Cohen O, Schneider D, Gurevich P, Halperin R, Bala U, Mozes M, Zusman I. The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study. Anticancer Res. 2002;22(2B):1231\u20138.","journal-title":"Anticancer Res"},{"key":"4013_CR21","doi-asserted-by":"crossref","unstructured":"Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Otsuka H, Kanomata N, Minami S, Eguchi S, Yano H. Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes. J Clin Pathol. 2016;","DOI":"10.1136\/jclinpath-2015-203506"},{"issue":"13","key":"4013_CR22","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1158\/0008-5472.CAN-11-0308","volume":"71","author":"ZC Hartman","year":"2011","unstructured":"Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS, Morse MA, Clay TM, Lyerly HK. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res. 2011;71(13):4380\u201391.","journal-title":"Cancer Res"},{"issue":"2","key":"4013_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cyto.2015.02.007","volume":"74","author":"MI Vazquez","year":"2015","unstructured":"Vazquez MI, Catalan-Dibene J, Zlotnik A. B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine. 2015;74(2):318\u201326.","journal-title":"Cytokine"},{"issue":"30","key":"4013_CR24","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/onc.2009.130","volume":"28","author":"M Walter","year":"2009","unstructured":"Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene. 2009;28(30):2745\u201355.","journal-title":"Oncogene"},{"key":"4013_CR25","doi-asserted-by":"crossref","unstructured":"Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013:46\u201351.","DOI":"10.1200\/EdBook_AM.2013.33.46"},{"issue":"1","key":"4013_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.mce.2013.06.003","volume":"382","author":"X Jiang","year":"2014","unstructured":"Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382(1):673\u201382.","journal-title":"Mol Cell Endocrinol"},{"issue":"21","key":"4013_CR27","first-page":"7889","volume":"61","author":"JA Coronella","year":"2001","unstructured":"Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61(21):7889\u201399.","journal-title":"Cancer Res"},{"issue":"3","key":"4013_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017876","volume":"6","author":"YT Chen","year":"2011","unstructured":"Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, et al. Multiple cancer\/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One. 2011;6(3):e17876.","journal-title":"PLoS One"},{"issue":"6","key":"4013_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038783","volume":"7","author":"FO Ademuyiwa","year":"2012","unstructured":"Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O'Connor TL, Levine EG, et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One. 2012;7(6):e38783.","journal-title":"PLoS One"},{"issue":"1","key":"4013_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4149\/neo_2016_006","volume":"63","author":"H Wang","year":"2016","unstructured":"Wang H, Sang M, Geng C, Liu F, Gu L, Shan B. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition. Neoplasma. 2016;63(1):44\u201356.","journal-title":"Neoplasma"},{"key":"4013_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","volume":"29","author":"S Luen","year":"2016","unstructured":"Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241\u201350.","journal-title":"Breast"},{"issue":"4","key":"4013_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330\u20136.","journal-title":"Nat Immunol"},{"issue":"9","key":"4013_CR33","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","volume":"72","author":"A Facciabene","year":"2012","unstructured":"Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72(9):2162\u201371.","journal-title":"Cancer Res"},{"key":"4013_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16\u201325.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"4013_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1046\/j.1440-1827.2003.01498.x","volume":"53","author":"M Yang","year":"2003","unstructured":"Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int. 2003;53(7):422\u20138.","journal-title":"Pathol Int"},{"issue":"4","key":"4013_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12282-012-0339-0","volume":"20","author":"M Mori","year":"2013","unstructured":"Mori M, Tsugawa K, Yamauchi H, Yagata H, Suzuki K, Ohde S, Soejima K, Nakamura S. Pathological assessment of microinvasive carcinoma of the breast. Breast Cancer. 2013;20(4):331\u20135.","journal-title":"Breast Cancer"},{"issue":"12","key":"4013_CR37","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2382::AID-CNCR12>3.0.CO;2-L","volume":"82","author":"SA Silver","year":"1998","unstructured":"Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82(12):2382\u201390.","journal-title":"Cancer"},{"issue":"3","key":"4013_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1245\/s10434-012-2640-8","volume":"20","author":"DN Margalit","year":"2013","unstructured":"Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE. Microinvasive breast cancer: ER, PR, and HER-2\/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013;20(3):811\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4013_CR39","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s13277-014-2652-z","volume":"36","author":"L Wang","year":"2015","unstructured":"Wang L, Zhang W, Lyu S, Liu X, Zhang T, Liu S, Qin Y, Tian X, Niu Y. Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol. 2015;36(4):2241\u20138.","journal-title":"Tumour Biol"},{"issue":"5","key":"4013_CR40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/0360-3016(92)90900-3","volume":"23","author":"LJ Solin","year":"1992","unstructured":"Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, Goodman RL. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1992;23(5):961\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4013_CR41","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.10451","volume":"94","author":"I de Mascarel","year":"2002","unstructured":"de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer. 2002;94(8):2134\u201342.","journal-title":"Cancer"},{"key":"4013_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/1756-0500-7-325","volume":"7","author":"CG Kuhar","year":"2014","unstructured":"Kuhar CG, Matos E. Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report. BMC Res Notes. 2014;7:325.","journal-title":"BMC Res Notes"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T05:03:23Z","timestamp":1603775003000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4013-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4013"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4013-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,3]]},"assertion":[{"value":"23 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients whose tissue and clinical data were used for this study have signed, already at admission to the Jean Perrin Cancer Centre, that they agree with the use of their tissues and clinical data for research purposes. The study presented in this article was approved by Comit\u00e9 d\u2019Ethique des Centres d\u2019Investigation Clinique de l\u2019inter-r\u00e9gion Rh\u00f4ne-Alpes-Auvergne. Approval reference: 00005921\/CE-CIC-GREN-17-14.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare having no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"129"}}